Connect Biopharma Holdings Limited
CNTB
$2.45
-$0.23-8.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.16% | -33.34% | -25.57% | -15.34% | 30.83% |
| Total Depreciation and Amortization | 1.12% | 4.68% | -1.16% | 9.49% | -10.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.19% | 12.67% | -8.80% | -54.87% | -20.60% |
| Change in Net Operating Assets | 349.56% | -115.21% | 10.39% | -112.18% | 306.25% |
| Cash from Operations | 35.37% | -38.24% | -26.43% | -329.45% | 82.17% |
| Capital Expenditure | 52.94% | 88.78% | -274.07% | 74.12% | -112.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.50% | 164.73% | 126.42% | -33.08% | -- |
| Cash from Investing | -23.44% | 179.70% | 124.85% | -30.94% | -10,623.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 232.56% | 33.54% | 7,950.00% | -98.11% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 232.56% | 33.54% | 7,950.00% | -98.11% | -- |
| Foreign Exchange rate Adjustments | -12.07% | -74.11% | 198.67% | 107.63% | -293.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.94% | 60.62% | 76.81% | -60.99% | -49.92% |